The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Open accessAbstract
BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. METHODS: In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic phase to receive either imatinib or interferon alfa plus cytarabine. Long-term analyses included overall survival, response to treatment, and serious adverse events. RESULTS: The median follow-up was 10.9 years. Given the high rate of crossover among patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of therapy before crossover in these patients (median, 0.8 years), the current analyses focused on patients who had been randomly assigned to receive imatinib. Among the patients in the imatinib group, the estimated overall survival rate at 10 years was 83.3%. Approximately half the patients (48.3%) who had been randomly assigned to imatinib completed study treatment with imatinib, and 82.8% had a complete cytogenetic response. Serious adverse events that were considered by the investigators to be related to imatinib were uncommon and most frequently occurred during the first year of treatment. CONCLUSIONS: Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not associated with unacceptable cumulative or late toxic effects. (Funded by Novartis Pharmaceuticals; IRIS ClinicalTrials.gov numbers, NCT00006343 and NCT00333840 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationNilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationBaccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Self-citationHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Self-citationPrognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationBower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Self-citationHochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Etienne, G., Dorlhiac-Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 839
Self-citationHasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L., & Ansari, H. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.850 · Cited by 819
Self-citationHasford, J., Baccarani, M., Hoffmann, V., Guilhot, J., Saussele, S., Rosti, G., Guilhot, F., Porkka, K., Ossenkoppele, G., Lindoerfer, D., et al. (2011) · Blood · doi:10.1182/blood-2010-12-319038 · Cited by 500
Self-citationHughes, T. P., Hochhaus, A., Branford, S., Müller, M. C., Kaeda, J. S., Foroni, L., Druker, B. J., Guilhot, F., Larson, R. A., O'Brien, S. G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273979 · Cited by 489
Self-citationApproval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen, M. H., Williams, G., Johnson, J. R., Duan, J. Z., Gobburu, J. V. S., Rahman, A., Benson, K. A., Leighton, J. K., Kim, S. K., Wood, R., et al. (2002) · PubMed · Cited by 462
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationJabbour, E., Kantarjian, H. M., Saglio, G., Steegmann, J. L., Shah, N. P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511592 · Cited by 395
Self-citationKantarjian, H., O'Brien, S., Jabbour, E., Garcia-Manero, G., Quintas-Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S., Kadia, T., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 334
Self-citationPfirrmann, M., Baccarani, M., Saussele, S., Guilhot, J., Cervantes, F., Ossenkoppele, G., Hoffmann, V. S., Castagnetti, F., Hasford, J., Hehlmann, R., et al. (2016) · Leukemia · doi:10.1038/leu.2015.261 · Cited by 307
Self-citationHehlmann, R., Müller, M. C., Lauseker, M., Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, M., Haferlach, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9020 · Cited by 300
Self-citationKalmanti, L., Saussele, S., Lauseker, M., Müller, M. C., Dietz, C. T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S. W., et al. (2015) · Leukemia · doi:10.1038/leu.2015.36 · Cited by 277
Self-citationGiles, F. J., le Coutre, P. D., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., Hughes, T. P., et al. (2013) · Leukemia · doi:10.1038/leu.2012.181 · Cited by 251
Self-citationThe concept of treatment-free remission in chronic myeloid leukemia
Saußele, S., Richter, J., Hochhaus, A., & Mahon, F.-X. (2016) · Leukemia · doi:10.1038/leu.2016.115 · Cited by 247
Self-citationRoy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B. J., Larson, R. A., O'Brien, S., So, C., Massimini, G., & Guilhot, F. (2006) · Blood · doi:10.1182/blood-2006-02-001495 · Cited by 216
Self-citationSaußele, S., Krauß, M.-P., Hehlmann, R., Lauseker, M., Proetel, U., Kalmanti, L., Hanfstein, B., Fabarius, A., Kraemer, D., Berdel, W. E., et al. (2015) · Blood · doi:10.1182/blood-2015-01-617993 · Cited by 203
Self-citationShah, N. P., Guilhot, F., Cortes, J. E., Schiffer, C. A., le Coutre, P., Brümmendorf, T. H., Kantarjian, H. M., Hochhaus, A., Rousselot, P., Mohamed, H., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532341 · Cited by 200
Self-citationDrug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
Hehlmann, R., Berger, U., Pfirrmann, M., Heimpel, H., Hochhaus, A., Hasford, J., Kolb, H.-J., Lahaye, T., Maywald, O., Reiter, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-055186 · Cited by 161
Self-citationHochhaus, A., Rosti, G., Cross, N. C. P., Steegmann, J. L., le Coutre, P., Ossenkoppele, G. J., Petrov, L., Masszi, T., Hellmann, A., Griškevičius, L., et al. (2015) · Leukemia · doi:10.1038/leu.2015.270 · Cited by 110
Self-citationGuilhot, J., Baccarani, M., Clark, R. E., Cervantes, F., Guilhot, F., Hochhaus, A., Kulikov, S. M., Mayer, J., Petzer, A. L., Rosti, G., et al. (2012) · Blood · doi:10.1182/blood-2011-10-383711 · Cited by 82
Self-citationMenger, L., Gouble, A., Marzolini, M. A. V., Pachnio, A., Bergerhoff, K. F., Henry, J. Y., Smith, J. N. P., Pulè, M. A., Moss, P. A. H., Riddell, S. R., et al. (2015) · Blood · doi:10.1182/blood-2015-08-664755 · Cited by 58
It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Westin, J. R., & Kurzrock, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0473 · Cited by 57
for the SAKK and the German CML Study Group, Gratwohl, A. A., Pfirrmann, M., Zander, A., Kröger, N. M., Beelen, D. W., Novotný, J., Nerl, C., Scheid, C., Spiekermann, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.281 · Cited by 56
Self-citationGuilhot, F., Druker, B. J., Larson, R. A., Gathmann, I., So, C., Waltzman, R. J., & O'Brien, S. G. (2009) · Haematologica · doi:10.3324/haematol.2009.010629 · Cited by 53
Self-citationMolecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?
Rumpold, H. F., & Webersinke, G. (2010) · Current Cancer Drug Targets · doi:10.2174/156800911793743619 · Cited by 37
Chihara, D., Ito, H. M., Matsuda, T., Katanoda, K., Shibata, A., Saika, K., Sobue, T., & Matsuo, K. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0197 · Cited by 20
Cited by
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Self-citationEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
“fraction and a low glomerular filtration rate should be observed carefully for related organ toxicity [4, 35].”
BackgroundInfluentialSelf-citationResolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 653
Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30192-x · Cited by 618
Self-citationG-quadruplexes: a promising target for cancer therapy
Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 533
Metadata
- Authors
- Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., Ortmann, C.-E., Menssen, H. D., Kantarjian, H., O’Brien, S. G., & Druker, B. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-09
- Volume
- 376
- Issue
- 10
- Pages
- 917-927
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2592060299
- Cited by
- 1,285
- References
- 36
- FWCI
- 83.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.